Lecanemab in DIAD: 6‐Month Amyloid PET Results from the DIAN‐TU‐001 Trial

Lecanemab reduced amyloid PET in symptomatic participants with DIAD at Week 24. The reduction in amyloid PET was in line with predictions based on PK/PD modeling developed from sporadic AD.

Authors

Institutions

Publication Details

Journal
Alzheimer s & Dementia
Published
2025-12-01
DOI
https://doi.org/10.1002/alz70859_105303
Primary Topic
Alzheimer's disease research and treatments
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Lecanemab in DIAD: 6‐Month Amyloid PET Results from the DIAN‐TU‐001 Trial

Kristin R. Wildsmith, Eric McDade, A. Charil, Pratik Bhagunde et al.
Alzheimer s & Dementia
Alzheimer's disease research and treatments
article

Lecanemab in DIAD: 6‐Month Amyloid PET Results from the DIAN‐TU‐001 Trial

Kristin R. Wildsmith, Eric McDade, A. Charil, Pratik Bhagunde, Guoqiao Wang, Randall J. Bateman, Brian A. Gordon, Tammie L.S. Benzinger, Larisa Reyderman, Jin Zhou, David Li
article en

Abstract

Lecanemab reduced amyloid PET in symptomatic participants with DIAD at Week 24. The reduction in amyloid PET was in line with predictions based on PK/PD modeling developed from sporadic AD.

Alzheimer s & DementiaVol. 21(S5)
Washington University in St. Louis (US), Eisai (United States) (US)
Openalex Percentile: Top 33%
Alzheimer's disease research and treatments
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.